Monte Rosa Therapeutics, Inc. (GLUE) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $18.98: Quality below floor (2.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Below-average business quality; Negative price momentum. (Note: Risk dimension 3.4/10 and A.R:R 3.4:1 are different metrics that happen to read the same number here.)
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally... Read more
Sell if holding. Engine safety override at $18.98: Quality below floor (2.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Below-average business quality; Negative price momentum. (Note: Risk dimension 3.4/10 and A.R:R 3.4:1 are different metrics that happen to read the same number here.) Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.5/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Unprofitable operations — net margin -31.2%. Quality floor flags this regardless of sector context.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $18.98: Quality below floor (2.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Below-average business quality; Negative price momentum. (Note: Risk dimension 3.4/10 and A.R:R 3.4:1 are different metrics that happen to read the same number here.) Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $17.66. Score 4.5/10, moderate confidence.
Take-profit target: $27.99 (+47.4% upside). Prior stop was $17.66. Stop-loss: $17.66.
Quality below floor (2.2 < 4.0).
Monte Rosa Therapeutics, Inc. trades at a P/E of N/A (forward -11.0). TrendMatrix value score: 6.2/10. Verdict: Sell.
15 analysts cover GLUE with a consensus score of 4.3/5. Average price target: $32.
What does Monte Rosa Therapeutics, Inc. do?Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small...
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.